Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC

INTRODUCTION: The Blood First Assay Screening Trial revealed the clinical applicability of blood-based next-generation sequencing to identify patients with ALK-positive NSCLC for alectinib treatment. To understand the relationship between tissue-based versus blood-based testing, we retrospectively i...

Descripción completa

Detalles Bibliográficos
Autores principales: Noé, Johannes, Bordogna, Walter, Archer, Venice, Smoljanovic, Vlatka, Hilton, Magalie, Woodhouse, Ryan, Mocci, Simonetta, Gadgeel, Shirish M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218556/
https://www.ncbi.nlm.nih.gov/pubmed/35756755
http://dx.doi.org/10.1016/j.jtocrr.2022.100341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218556/
https://www.ncbi.nlm.nih.gov/pubmed/35756755
http://dx.doi.org/10.1016/j.jtocrr.2022.100341

Ejemplares similares